Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity

We have previously shown that the addition of the raltegravir/elvitegavir (RAL/EVG) primary resistance mutation N155H to the R263K dolutegravir (DTG) resistance mutation partially compensated for the fitness cost imposed by R263K while also slightly increasing DTG resistance in vitro (K. Anstett, T....

Full description

Saved in:
Bibliographic Details
Published in:J Virol
Main Authors: Anstett, Kaitlin, Fusco, Robert, Cutillas, Vincent, Mesplède, Thibault, Wainberg, Mark A.
Format: Artigo
Language:Inglês
Published: American Society for Microbiology 2015
Subjects:
Vaccines and Antiviral Agents
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4580168/
https://ncbi.nlm.nih.gov/pubmed/26246578
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.01725-15
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items